QUOTE AND NEWS
GenEng News  Apr 20  Comment 
A scientific team led by University of California San Diego School of Medicine researchers says it has identified the cause that may explain why some people develop autism—rare inherited variants in regions of paternal noncoding DNA. Previous...
FiercePharma  Apr 18  Comment 
In a new approach to the pricing and payer issues beleaguering pharma in general and diabetes drugmakers in particular, Novo Nordisk has teamed up on a project that puts patients with diabetes to work earning discounted copays and other incentives...
FierceBiotech  Apr 6  Comment 
Novo Nordisk has moved into sickle cell disease through a licensing deal with EpiDestiny. The $400 million deal gives Novo worldwide rights to an epigenetic treatment of the disease that is closing in on the start of a phase 2 trial.
FiercePharma  Mar 26  Comment 
Competition in the basal insulin market has been fierce, with new competition and payer pressure stymieing growth in the field. But Novo Nordisk just won an FDA approval that could help it stand out in the crowded category.
FierceBiotech  Mar 26  Comment 
Venture capital firm Novo Holdings says it is looking to fuel more early- and late-stage biotechs.
FiercePharma  Mar 23  Comment 
Just weeks after Novo Nordisk lost out to Sanofi in a race to buy the pipeline-boosting biotech Ablynx, the Danish drugmaker is far from out of the M&A game. For its new board chairman, Novo chose Helge Lund, an oil-industry veteran with plenty of...
GenEng News  Mar 22  Comment 
Pathogenic de novo mutations in coding DNA have been implicated in neurodevelopmental disorders such as developmental brain dysfunction, which can lead to impaired learning and language. In fact, according to one estimate, 42% of patients...
FiercePharma  Mar 19  Comment 
Novo Nordisk’s closely watched semaglutide has already shown it can spur weight loss in diabetic patients. Now it’s added evidence that it can help nondiabetic obesity patients shed pounds, too.





You may also be interested in articles related to Novo Nordisk A/S (NVO):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki